إدارة النوبات من الخط الأول في اضطراب طيف التهاب النخاع البصري

References

DOI: 10.1007/s00415-024-12288-2

• Attack therapy must be initiated as early as possible in NMOSD attacks.
• Methylprednisolone (MP) should be usually administered intravenously (i. v.) at a dose of 1000 mg per day for 3–5 days, followed by an oral MP taper (starting with either 1 mg/kg/day or 20–30 mg/day and then tapered to 10–15 mg/day within 2–3 weeks) in combination with proton pump inhibition and thrombosis prophylaxis.
• Low-dose oral glucocorticoids for up to 3–6 months are also considered beneficial for preventing subsequent early attacks, although there is a lack of prospective studies.
• Following attack therapy (high-dose glucocorticoid therapy and/or apheresis therapy), an oral taper of glucocorticoids should be administered for up to 3–6 months to prevent subsequent attacks, especially at the start or switch of long-term immunotherapy.